Related references
Note: Only part of the references are listed.Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
Bernard M. Y. Cheung et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Idd Loci Synergize to Prolong Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice
Julie Mangada et al.
DIABETES (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Weight Change in Diabetes and Glycemic and Blood Pressure Control
Adrianne C. Feldstein et al.
DIABETES CARE (2008)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effect of BMI on lifetime risk for diabetes in the US
K. M. V. Narayan et al.
DIABETES CARE (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data
Andrew P. Yu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Obesity and cardiovascular risk factors in type 2 diabetes:: results from the Swedish National Diabetes Register
M Ridderstråle et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Influence of obesity on cardiovascular risk.: Twenty-three-year follow-up of 22 025 men from an urban Swedish population
S Jonsson et al.
INTERNATIONAL JOURNAL OF OBESITY (2002)
Intentional weight loss and mortality among overweight individuals with diabetes
DF Williamson et al.
DIABETES CARE (2000)
Share Paper
